167 related articles for article (PubMed ID: 26243165)
21. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
23. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension.
Picca M; Agozzino F; Pelosi G
Adv Ther; 2004; 21(2):76-86. PubMed ID: 15310081
[TBL] [Abstract][Full Text] [Related]
24. The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension.
Boydak B; Nalbantgil S; Yilmaz H; Zoghi M; Ozerkan F; Nalbantgil I; Onder R
Saudi Med J; 2004 Dec; 25(12):1975-8. PubMed ID: 15711679
[TBL] [Abstract][Full Text] [Related]
25. Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats.
Amenta F; Peleg E; Tomassoni D; Sabbatini M; Rosenthal T
Hypertension; 2003 Jun; 41(6):1330-5. PubMed ID: 12719440
[TBL] [Abstract][Full Text] [Related]
26. Lercanidipine in the treatment of hypertension.
Beckey C; Lundy A; Lutfi N
Ann Pharmacother; 2007 Mar; 41(3):465-73. PubMed ID: 17341540
[TBL] [Abstract][Full Text] [Related]
27. [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension].
Tedesco MA; Ratti G; Aquino D; Caccavale A; Acitorio M; Rocereto A; Cosimi R; Coppolino P; Iarussi D; Iacono A
Cardiologia; 1998 Jan; 43(1):53-9. PubMed ID: 9534293
[TBL] [Abstract][Full Text] [Related]
28. Beneficial effects of the combination of nifedipine and losartan in hypertensive Dahl salt-sensitive rats.
Tinel H
J Cardiovasc Pharmacol; 2007 Jul; 50(1):75-82. PubMed ID: 17666919
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients.
Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H; Suzuki H
J Cardiovasc Pharmacol; 2004 Mar; 43(3):380-6. PubMed ID: 15076221
[TBL] [Abstract][Full Text] [Related]
30. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients.
De Rosa ML; Cardace P; Rossi M; Baiano A; de Cristofaro A
J Hum Hypertens; 2002 Feb; 16(2):133-40. PubMed ID: 11850771
[TBL] [Abstract][Full Text] [Related]
31. Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension.
Ye P; Wu CE; Sheng L; Li H
J Altern Complement Med; 2009 Jul; 15(7):719-25. PubMed ID: 19552598
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of psychosomatic symptomatology in hypertensive patients treated with lercanidipine (LERCAPSICO study)].
Abellán Alemán J; Martínez García JF; Merino Sánchez J; Gil Guillén V; Latorre Hernández J; Fernández Montero F; Navarro Lima A;
An Med Interna; 2003 Jun; 20(6):287-91. PubMed ID: 12848598
[TBL] [Abstract][Full Text] [Related]
33. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
34. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
[TBL] [Abstract][Full Text] [Related]
35. Lercanidipine in hypertension.
Borghi C
Vasc Health Risk Manag; 2005; 1(3):173-82. PubMed ID: 17319103
[TBL] [Abstract][Full Text] [Related]
36. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study.
Cherubini A; Fabris F; Ferrari E; Cucinotta D; Antonelli Incalzi R; Senin U
Arch Gerontol Geriatr; 2003; 37(3):203-12. PubMed ID: 14511846
[TBL] [Abstract][Full Text] [Related]
37. [A reduction of left ventricular hypertrophy and an improvement in diastolic function after therapy with nifedipine retard in patients with hypertensive cardiopathy].
Amici E; Patruno N; Natale E; Marsocci A; Gambelli G
Cardiologia; 1993 Sep; 38(9):585-91. PubMed ID: 8287388
[TBL] [Abstract][Full Text] [Related]
38. Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters.
Lin TH; Voon WC; Yen HW; Huang CH; Su HM; Lai WT; Sheu SH
Kaohsiung J Med Sci; 2006 Apr; 22(4):177-83. PubMed ID: 16679299
[TBL] [Abstract][Full Text] [Related]
39. Fixed-dose combination lercanidipine/enalapril.
Hair PI; Scott LJ; Perry CM
Drugs; 2007; 67(1):95-106; discussion 107-8. PubMed ID: 17209666
[TBL] [Abstract][Full Text] [Related]
40. Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats.
Alvarez BV; Ennis IL; De Hurtado MC; Cingolani HE
Can J Cardiol; 2002 Jun; 18(6):667-72. PubMed ID: 12107424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
